A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.

A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.

Item
http://www.wikidata.org/entity/Q34431384
Immunotherapy for lung cancer: advances and prospectsUpdate on the challenges and recent advances in cancer immunotherapyAdoptive immunotherapy with interleukin-2 & induced killer cells in non-small cell lung cancer: A systematic review & meta-analysisRandomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer.NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours.Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells.Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study.Cell Based Autologous Immune Enhancement Therapy (AIET) after Radiotherapy in a Locally Advanced Carcinoma of the Cervix.Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study.Relapsed small cell lung cancer: treatment options and latest developments.Immunotherapy prospects in the treatment of lung cancer and mesothelioma.Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis.Is there a room for immune checkpoint inhibitors in early stage non-small cell lung cancer?Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS)
P2860

A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.

Item
http://www.wikidata.org/entity/Q34431384
description
1997 nî lūn-bûn
@nan
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
A phase III randomized study o ...... ion of primary lung carcinoma.
@ast
A phase III randomized study o ...... ion of primary lung carcinoma.
@en
A phase III randomized study o ...... ion of primary lung carcinoma.
@nl
type
label
A phase III randomized study o ...... ion of primary lung carcinoma.
@ast
A phase III randomized study o ...... ion of primary lung carcinoma.
@en
A phase III randomized study o ...... ion of primary lung carcinoma.
@nl
prefLabel
A phase III randomized study o ...... ion of primary lung carcinoma.
@ast
A phase III randomized study o ...... ion of primary lung carcinoma.
@en
A phase III randomized study o ...... ion of primary lung carcinoma.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
A phase III randomized study o ...... ion of primary lung carcinoma.
@en
P2093
P304
P31
P356
10.1002/(SICI)1097-0142(19970701)80:1<42::AID-CNCR6>3.3.CO;2-V
P407
P433
P478
P577
P698
P921